Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025382 | 0.86 | APEX1 (0.69) | APEX1CASP6TSHRLMNAALDH1A1 | |
| SCHEMBL3866808 | 0.83 | APEX1 (0.66) | APEX1CASP6TSHRLMNAALDH1A1 | |
| SCHEMBL1025384 | 0.83 | APEX1 (0.66) | APEX1CASP6TSHRLMNAALDH1A1 | |
| SCHEMBL1996412 | 0.80 | APEX1 (0.70) | APEX1CASP6TSHRLMNAALDH1A1 | |
| SCHEMBL10650251 | 0.80 | MAPT (0.79) | APEX1CASP6LMNAALDH1A1MAPT | |
| SCHEMBL6089975 | 0.80 | APEX1 (0.61) | APEX1CASP6TSHRLMNAALDH1A1 | |
| SCHEMBL1923978 | 0.79 | BCL2L1 (0.74) | APEX1CASP6LMNAALDH1A1MAPT | |
| SCHEMBL2001981 | 0.78 | APEX1 (0.72) | APEX1CASP6TSHRLMNAALDH1A1 | |
| SCHEMBL29577830 | 0.78 | CASP6 (1.00) | APEX1CASP6TSHRLMNAHCAR3 | |
| SCHEMBL504055 | 0.78 | CASP6 (1.00) | APEX1CASP6TSHRLMNAHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117689-B1 | BONE MORPHOGENETIC PROTEIN ANTAGONISTS BASED ON THE MATURE PROTEIN | BIOPH BIOTECH ENTW PHARM GMBH (DE) | 2012-03-28 | — | — | EP | disclosed |
| EP-1700114-A4 | METHOD FOR ENRICHMENT/SEPARATION OF PROTEIN OR PEPTIDE | SHIMADZU CORP (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070112181-A1 | Method for enrichment/seperation of protein or peptide | SHIMADZU CORPORATION (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7132397-B1 | Bone morphogenetic protein antagonist based on the mature protein | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBH (DE) | 2006-11-07 | — | — | US | disclosed |
| EP-1700114-A2 | METHOD FOR ENRICHMENT/SEPARATION OF PROTEIN OR PEPTIDE | SHIMADZU CORPORATION (JP) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005062725-A2 | METHOD FOR ENRICHMENT/SEPARATION OF PROTEIN OR PEPTIDE | SHIMADZU CORPORATION (JP) | 2005-07-14 | — | — | WO | disclosed |
| EP-1117689-A1 | BONE MORPHOGENETIC PROTEIN ANTAGONISTS BASED ON THE MATURE PROTEIN | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000021998-A1 | BONE MORPHOGENETIC PROTEIN ANTAGONIST BASED ON THE MATURE PROTEIN | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBH (DE) | 2000-04-20 | — | — | WO | disclosed |
| US-5597821-A | ANTITUMOR AGENTS | MERCK SHARP & DOHME CORP. | 1997-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112181-A1 | Method for enrichment/seperation of protein or peptide | PTMS, MAX, PREP | APEX1 547/4885CASP6 2767/4885TSHR 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.